Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review

References

• Magliano DJ, Boyko EJ, committee IDFDAtes. IDF Diabetes Atlas. Idf diabetes atlas. Brussels: International Diabetes Federation© International Diabetes Federation, 2021; 2021.
   Google Scholar
• Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008 Nov;88(11):1322–1335.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Standards of medical care in diabetes–2014. Diabetes Care. 2014 Jan;37(Suppl 1):S14–80.
   PubMedGoogle Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017 Apr;40(4):468–475.
   PubMed Web of Science ®Google Scholar
• Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24): 2560–2572.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251–260.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017 5; May(5): 341–354.
   Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018 Feb;41(2):258–266.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017 5;May(5):355–366.
   Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291–2301.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018 Apr;6(4):275–286.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834–844.
   PubMed Web of Science ®Google Scholar
• Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 May;7(5):356–367.
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100–109.
   PubMed Web of Science ®Google Scholar
• Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021 Feb;23(2):404–414.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Blonde L, Bailey T, Strong J, et al. Real-world evidence in diabetes: relevance to clinical practice. J Fam Pract. 2019 Apr;68(3Suppl):jfp_68031.
   PubMedGoogle Scholar
• Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care. 2017 Nov;40(11):1469–1478.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.
   PubMed Web of Science ®Google Scholar
• GA Wells BS, O’Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [cited 2022 Sept 12]. Available from: https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study) [Article]. Diabetes Obesity Metab. 2020;22(11):2013–2020.
   PubMed Web of Science ®Google Scholar
• Iacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with Type 2 diabetes and obesity [Article]. J Endocr Soc. 2020;4(4):1–9.
   Web of Science ®Google Scholar
• Yale JF, Catarig AM, Grau K, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study [Article]. Diabetes Obesity Metab. 2021;23(10):2269–2278.
   PubMed Web of Science ®Google Scholar
• Ekberg NR, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study [Article]. Prim Care Diabetes. 2021 Oct;15(5):871–878.
   PubMed Web of Science ®Google Scholar
• Hansen KB, Svendstrup M, Lund A, et al. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic [Article]. Diabetic Med. 2021;38(10):10.
   Web of Science ®Google Scholar
• Hepprich M, Zillig D, Florian-Reynoso MA, et al. Switch-to-semaglutide study (STS-Study): a retrospective cohort study [Article]. Diabetes Therapy. 2021;12(3):943–954.
   PubMed Web of Science ®Google Scholar
• Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK Multicentre, Prospective, Observational Study [Article]. Diabetes Therapy. 2021;12(11):2891–2905.
   PubMed Web of Science ®Google Scholar
• Jain AB, Kanters S, Khurana R, et al. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study [Article]. Diabetes Therapy. 2021;12(2):527–536.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Kirk AR, Lophaven S, et al. Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT Study [Article]. Diabetes Therapy. 2021;12(3):879–896.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Yokokawa H, Nagamine T, et al. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists [Article]. J Diabetes Metab Disord. 2021;20(2):2121–2128.
   PubMed Web of Science ®Google Scholar
• Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study [Article]. Diabetes Res Clin Pract. 2021;178:108931.
   PubMed Web of Science ®Google Scholar
• Tofé S, Argüelles I, Mena E, et al. An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain [Article]. Endocrinol Metab. 2021;2.
   Google Scholar
• Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study [Article]. Diabetes Therapy. 2021;12(3):801–811.
   PubMed Web of Science ®Google Scholar
• Hayek AAA, Dawish MAA. Evaluation of patient-reported satisfaction and clinical efficacy of once-weekly semaglutide in patients with type 2 diabetes: an ambispective study. Adv Ther. 2022;39(4):4.
   Web of Science ®Google Scholar
• Bueno BA, Soler MJ, Perez-Belmonte L, et al. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice [Article]. Clin Kidney J. 2022;15(8):1593–1600.
   Web of Science ®Google Scholar
• Di Loreto C, Minarelli V, Nasini G, et al. Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: glucagon-like peptide receptor agonist naive or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational study in Umbria [Article]. Diabetes Therapy. 2022 Mar;13(3):551–567.
   PubMed Web of Science ®Google Scholar
• Marzullo P, Daffara T, Mele C, et al. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients [Article]. J Endocrinol Invest. 2022 Aug;45(8):1587–1598.
   PubMed Web of Science ®Google Scholar
• Rana KB, Britnell SR, Gilbertson ME, et al. Comparison of the effectiveness of liraglutide vs semaglutide in a veteran population [Article]. J Pharm Pract 2022 089719002210871. DOI: 10.1177/08971900221087127
   Web of Science ®Google Scholar
• Harkin P, O’Connell J, O’Shea D. Early experience with semaglutide in clinical practice [Conference Abstract]. Ir J Med Sci. 2019;188:S230.
   Web of Science ®Google Scholar
• Cardenas J, Sanchez GN, Miguel SPR, et al. Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain [Conference Abstract]. Endocrine Abstracts, Virtual. 2020.
   Google Scholar
• Ferrer-García JC, Galera RA, Arribas L, et al. Semaglutide added to treatment or changed from other GLP-1 receptor agonist in type 2 diabetes: a study to evaluate real-world effectiveness [Conference Abstract]. Diabetes, Virtual. 2020;69.
   Google Scholar
• Luiza LB, Miguel SPR, Cardenas J, et al. Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in Spain [Conference Abstract]. Endocrine Abstracts, Virtual. 2020.
   Google Scholar
• Redondo E, Serrano MC, Leon S, et al. Changes in metabolic control and body composition with Semaglutide sc in patients with type 2 diabetes mellitus [Conference Abstract]. Endocrine Abstracts, Virtual. 2020.
   Google Scholar
• Tong J, Jain A, Stafford S. Comparative Analysis of A1c and Weight Reduction Potential of Subcutaneous GLP-1 Receptor Agonists in a Real-World Setting [Conference Abstract]. Canadian Journal of Diabetes, Virtual. 2020;44(7):S23–S24.
   Google Scholar
• Allum M, Buckley A, Lessan N, et al. Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates [Conference Abstract]. Endocrine Abstracts, Virtual. 2021;77.
   Google Scholar
• Andrea FV, Imm J, Ana MGP, et al. Effectiveness of semaglutide in obese patients with type 2 diabetes. a six-month clinical experience [Conference Abstract]. Endocrine Abstracts, Virtual. 2021;73.
   Google Scholar
• Balcazar CM, Zambrano J, Garcia AF, et al. Semaglutide once weekly in persons with type 2 diabetes: real-world analysis of the Colombian diabetes registry (COL-REAL 1 Study) [Conference Abstract]. Metabolism: Clinical and Experimental, Virtual. 2021;116.
   Google Scholar
• Cárdenas-salas JJ, Sierra R, Luiza Luca B, et al. Semaglutide in patients with type 2 diabetes: real-world data from Spain [Conference Abstract]. Diabetes, Virtual. 2021;70(SUPPL 1).
   Google Scholar
• De Lucas MDG, Pérez-Belmonte LM, Aviles B, et al. Semaglutide achieves better metabolic and weight control than other GLP-1 ra in real life after 12 months of follow-up [Conference Abstract]. Diabetes, Virtual. 2021;70(SUPPL 1).
   Google Scholar
• Thant AA, Atkinson R, Kapoor A, et al. Comparison of efficacy of weekly glucagon-like peptide-1 (GLP-1) analogue therapies [Conference Abstract]. Diabetic Medicine, Virtual. 2021;38(SUPPL 1):100.
   Google Scholar
• Cardenas SJJ, Poyatos RMS, Luiza LB, et al. REAL life study of SEMaglutide in Patients with Type 2 diabetes in Spain (REALSEM-SP): retrospective clinical study on the efficacy, adherence, and safety with Semaglutide [Conference Abstract]. Endocrine Abstracts, Milan. 2022;81.
   Google Scholar
• Ruan Z, Yang L, Shi H, et al. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221–233.
   PubMed Web of Science ®Google Scholar
• Ruan Z, Ung COL, Shen Y, et al. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Ther. 2022 Oct;13(10):1737–1753.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl1):S98–S110.
   PubMedGoogle Scholar